NGR peptide Trifluoroacetate |
| Catalog No.GC36733 |
NGR peptide Trifluoroacetate containing the asparagine-glycine-arginine (NGR) motif is recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NGR peptide Trifluoroacetate containing the asparagine-glycine-arginine (NGR) motif is recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature. CD13/aminopeptidase N (APN) receptor[1]
NGR peptide can selectively bind to APN/CD13 either immune-captured or expressed on the surface of cells, the receptor of the tumor-homing NGR peptide was suspected to be APN/CD13. The NGR peptide is reported to have the greatest tumor selectivity. An anti-cancer drug Doxorubicin (DOX) coupled to an NGR peptide displays enhanced anti-tumor effects with even lower toxicity than the free drug itself[2].
NGR peptide imaging in vivo not only provides more insight into NGR's targeting process, including bio-distribution and pharmacokinetics, but also reveals angiogenic activities related to tumor progression and malignancy[2].
[1]. Enyedi KN, et al. NGR-peptide-drug conjugates with dual targeting properties. NGR-peptide-drug conjugates with dual targeting properties. [2]. Wang RE, et al. Development of NGR peptide-based agents for tumor imaging. Am J Nucl Med Mol Imaging. 2011;1(1):36-46.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *